Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection for non-small cell lung cancer and mesothelioma. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Metrics to compare | EGRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEGRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 5.3x | −0.5x | |
PEG Ratio | 0.00 | 0.12 | 0.00 | |
Price/Book | 0.0x | 3.6x | 2.6x | |
Price / LTM Sales | 0.0x | 5.1x | 3.3x | |
Upside (Analyst Target) | 0.0% | 302.7% | 45.0% | |
Fair Value Upside | Unlock | 14.5% | 5.1% | Unlock |